IL202375A0 - Pyrazolopyrimidinone kinase inhibitor - Google Patents

Pyrazolopyrimidinone kinase inhibitor

Info

Publication number
IL202375A0
IL202375A0 IL202375A IL20237509A IL202375A0 IL 202375 A0 IL202375 A0 IL 202375A0 IL 202375 A IL202375 A IL 202375A IL 20237509 A IL20237509 A IL 20237509A IL 202375 A0 IL202375 A0 IL 202375A0
Authority
IL
Israel
Prior art keywords
pyrazolopyrimidinone
kinase inhibitor
kinase
inhibitor
pyrazolopyrimidinone kinase
Prior art date
Application number
IL202375A
Original Assignee
Agennix Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agennix Ag filed Critical Agennix Ag
Publication of IL202375A0 publication Critical patent/IL202375A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL202375A 2007-05-29 2009-11-26 Pyrazolopyrimidinone kinase inhibitor IL202375A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93215507P 2007-05-29 2007-05-29
EP07113226A EP2019101A1 (en) 2007-07-26 2007-07-26 Pyrazol[3,4-d]pyrimidin-4-one useful as Kinase Inhibitor
PCT/EP2008/056569 WO2008145678A1 (en) 2007-05-29 2008-05-28 Pyrazolopyrimidinone kinase inhibitor

Publications (1)

Publication Number Publication Date
IL202375A0 true IL202375A0 (en) 2010-06-30

Family

ID=38556321

Family Applications (1)

Application Number Title Priority Date Filing Date
IL202375A IL202375A0 (en) 2007-05-29 2009-11-26 Pyrazolopyrimidinone kinase inhibitor

Country Status (19)

Country Link
US (2) US8304418B2 (en)
EP (2) EP2019101A1 (en)
JP (1) JP2010528088A (en)
KR (1) KR20100040806A (en)
CN (1) CN101765600A (en)
AR (1) AR066737A1 (en)
AT (1) ATE522533T1 (en)
AU (1) AU2008257534A1 (en)
CA (1) CA2689090A1 (en)
DK (1) DK2170891T3 (en)
EA (1) EA200901536A1 (en)
ES (1) ES2370677T3 (en)
HR (1) HRP20110768T1 (en)
IL (1) IL202375A0 (en)
MX (1) MX2009012832A (en)
SI (1) SI2170891T1 (en)
TW (1) TW200906831A (en)
WO (1) WO2008145678A1 (en)
ZA (1) ZA200908943B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5801285B2 (en) * 2009-04-29 2015-10-28 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ CDK inhibitor salt
WO2013059634A1 (en) 2011-10-20 2013-04-25 The Regents Of The University Of California Use of cdk9 inhibitors to reduce cartilage degradation
CN106458919B (en) * 2014-05-13 2019-03-15 广东东阳光药业有限公司 A kind of preparation method of intermediate
JP6930913B2 (en) 2014-10-14 2021-09-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ Usage of CDK9 and BRD4 inhibitors to inhibit inflammation

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3916889A (en) * 1973-09-28 1975-11-04 Sandoz Ag Patient ventilator apparatus
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4710384A (en) * 1986-07-28 1987-12-01 Avner Rotman Sustained release tablets made from microcapsules
EG18377A (en) * 1986-09-19 1993-04-30 Lilly Co Eli Process for preparing glycopeptide antibiotics
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (en) * 1989-03-22 1991-07-25 Bioresearch Spa USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS.
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
DE69329503T2 (en) * 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutic use of chimeric and labeled antibodies directed against a differentiation antigen, the expression of which is restricted to human B lymphocyte, for the treatment of B cell lymphoma
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (en) * 1994-07-07 1997-05-07 Recordati Chem Pharm CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN
US6531477B1 (en) * 1998-10-13 2003-03-11 Dupont Pharmaceuticals Company 6-substituted pyrazolo [3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
US6559152B2 (en) * 1998-10-13 2003-05-06 Dupont Pharmaceuticals Company 6-substituted pyrazolo[3,4-d]pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
EP1156060B1 (en) 2000-05-12 2007-06-27 GPC Biotech AG Human peptides/proteins causing or leading to the killing of cells including lymphoid tumor cells
IT1317975B1 (en) 2000-06-16 2003-07-21 Christian Pio Pedulla MULTI-WHEEL JACK.
WO2003063764A2 (en) * 2001-07-10 2003-08-07 Bristol-Myers Squibb Pharma Company 6-SUBSTITUTED PYRAZOLO [3,4-d] PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS
JP2005511535A (en) * 2001-10-15 2005-04-28 ジーピーシー バイオテック インク． Cyclin-dependent kinase inhibitors, compositions and uses thereof
AU2004230867B2 (en) * 2003-04-07 2010-09-09 Agennix Usa Inc. Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
US8084457B2 (en) 2003-09-15 2011-12-27 Lead Discovery Center Gmbh Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
AU2004309415B2 (en) 2003-12-23 2010-08-26 Agennix Usa Inc. Inhibitors of cyclin-dependent kinases, compositions and uses related thereto

Also Published As

Publication number Publication date
JP2010528088A (en) 2010-08-19
CA2689090A1 (en) 2008-12-04
ES2370677T3 (en) 2011-12-21
EA200901536A1 (en) 2010-06-30
US8304418B2 (en) 2012-11-06
TW200906831A (en) 2009-02-16
US20100160350A1 (en) 2010-06-24
HRP20110768T1 (en) 2011-11-30
US20130035349A1 (en) 2013-02-07
EP2170891B1 (en) 2011-08-31
CN101765600A (en) 2010-06-30
WO2008145678A1 (en) 2008-12-04
SI2170891T1 (en) 2011-12-30
EP2170891A1 (en) 2010-04-07
AR066737A1 (en) 2009-09-09
ZA200908943B (en) 2010-08-25
MX2009012832A (en) 2010-05-17
ATE522533T1 (en) 2011-09-15
DK2170891T3 (en) 2011-12-12
KR20100040806A (en) 2010-04-21
EP2019101A1 (en) 2009-01-28
AU2008257534A1 (en) 2008-12-04

Similar Documents

Publication Publication Date Title
IL197381A0 (en) Kinase inhibitor
HK1133641A1 (en) Kinase inhibitor compounds
ZA201004942B (en) Ptrrolopyrazine kinase inhibitors
HK1137295A1 (en) Kinase inhibitor compounds
HK1176601A1 (en) Ire-1a inhibitors ire-1a
IL213464A0 (en) Kinase inhibitor compounds
ZA201002543B (en) Polo-like kinase inhibitors
ZA200900109B (en) Pyrrolotriazine kinase inhibitors
HK1140767A1 (en) P70 s6 kinase inhibitors p70 s6
HK1151291A1 (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
IL194424A0 (en) 4-anilinoquinoline-3-carboxamides as csf-1r kinase inhibitors
EP2166857A4 (en) Kinase inhibitor compounds
EP2231152A4 (en) Thienopyranones as kinase inhibitors
GB0603522D0 (en) Kinase inhibition
EP2177529A4 (en) Novel -secretase inhibitor
ZA200908943B (en) Pyrazolopyrimidinone kinase inhibitor
EP2222662A4 (en) Kynurenine-aminotransferase inhibitors
IL197981A0 (en) Kinase inhibitors
GB0714941D0 (en) Inhibitors
GB0606238D0 (en) Kinase inhibition
GB0720364D0 (en) Inhibitor
GB0713152D0 (en) Phosphodlesterase inhibitors
GB0707498D0 (en) Novel inhibitors
GB0707493D0 (en) Novel inhibitors
GB0707499D0 (en) Novel inhibitors